Finland's Oriola Q4 net sales rise 13.9% on distribution, wholesale strength

Oriola Oyj

25/02/2026 06:38

Overview

Finland pharmaceutical distributor's Q4 net sales rose 13.9% yr/yr

Adjusted EBITDA for Q4 increased to EUR 9.9 mln

Company plans new distribution center in Finland, valued at EUR 110-120 mln

Outlook

Oriola expects adjusted EBITDA to increase in 2026 from EUR 35.1 mln in 2025

Pharmaceutical distribution market expected to grow, driven by high-value products

Geopolitical uncertainty and availability issues of certain pharmaceuticals expected to continue

Result Drivers

STRONG PARTNERSHIPS - Distribution segment's solid Q4 results driven by strong partnerships and increased value-adding services

WHOLESALE GROWTH - Investments in Finland's commercial capabilities and special-licensed medicines boosted Wholesale segment growth

PARALLEL IMPORT - Strong performance in Sweden driven by weight-loss medicines

Company press release: ID:nWkr2nxDkh

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
EUR 502 mln
Q4 EPS
-EUR 0.10


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Oriola Oyj is €1.25, about 11.2% above its February 24 closing price of €1.12

The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 12 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)